Sanofi

This early-stage trial is testing several new vaccine formulas against RSV and H5N1 bird flu in 570 healthy adults aged 18 to 49. The main goals are to check safety and see how well the vaccines trigger an immune response. Participants will receive one or two shots and be followe…

This Phase 3 trial tests a new yellow fever vaccine (vYF) in about 2,440 healthy children aged 9 months to 5 years. Researchers will compare vYF to two licensed vaccines (Stamaril and YF-VAX) to see if it triggers a strong immune response and is safe. Some children will also rece…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children and teens with sickle cell disease, aged 2 to 17. The goal is to see if it's safe and helps the body make antibodies better than the current 20-valent vaccine. Participants get one shot and are monitore…

This study tests a new mRNA vaccine designed to prevent chlamydia, a common sexually transmitted infection. About 1,560 adults aged 18 to 29 who are at higher risk of infection will receive either a low, medium, or high dose of the vaccine or a placebo. Researchers will monitor s…

This program provides early access to the experimental drug venglustat for children and adults with Type 3 Gaucher disease who have brain-related symptoms. Participants must be at least 12 years old, weigh at least 15 kg, and be stable on standard enzyme replacement therapy. The …

This phase 3 trial tests duvakitug, an injected drug, in about 980 adults with moderate to severe Crohn's disease who haven't improved with other treatments. The study is double-blind and placebo-controlled, meaning some participants get the drug and some get a dummy shot. The go…

This study tests whether teplizumab, a drug already approved in the US, can safely delay the start of full-blown type 1 diabetes in Japanese people aged 8 to 34 who are at high risk (Stage 2). Participants will receive a 14-day IV treatment and be monitored for side effects and h…

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…

This phase 3 study tests whether the oral drug rilzabrutinib can prevent disease flares in adults with active IgG4-related disease, a rare condition causing swelling and organ damage. About 124 participants will receive either rilzabrutinib or a placebo for 52 weeks, alongside st…

This study tests an experimental drug called SAR445399 in 144 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes abscesses and tunnels under the skin. Participants will receive one of two doses of the drug or a placebo for 32 weeks.…

This Phase 3 trial tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a bilateral lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The study compares belumosudil to a placebo, both given …

This study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …

This phase 3 trial is testing a drug called fitusiran in about 85 boys aged 1 to under 12 with severe hemophilia A or B, including those with inhibitors that make standard treatments less effective. The drug is given as a regular shot under the skin to help prevent bleeding episo…

This study tests whether the drug frexalimab can prevent kidney transplant rejection better than the standard drug tacrolimus. About 526 adults receiving their first kidney transplant will be randomly assigned to one of the two treatments and followed for up to 5 years. The main …

This study tests whether adding sarilumab (a drug that calms inflammation) to a slow steroid taper can help people with early polymyalgia rheumatica achieve lasting remission. About 300 adults aged 50 and older will receive either sarilumab or a placebo, along with a 52-week pred…

This Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …

This Phase 3 trial tests whether the oral drug rilzabrutinib can lower the number of painful vaso-occlusive crises in people with sickle cell disease. About 192 participants aged 10 to 65 will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug …

This study tests an experimental drug called SAR441566 in about 204 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. Participants will receive either the drug or a placebo for up to 52 weeks t…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed first-line treatment. The goal is to see if the drug can raise platelet c…

This phase 3 study tests whether duvakitug can help people with moderate-to-severe Crohn's disease maintain remission. About 751 participants who responded to prior treatment will receive either duvakitug or a placebo injection for up to 40 weeks, with an option to continue in an…

This study tests an experimental drug called SAR445399 in 70 adults aged 18-80 with non-cystic fibrosis bronchiectasis, a lung condition causing mucus buildup and infections. Participants receive either the drug or a placebo for 24 weeks to see if it reduces mucus plugs seen on C…

This umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different s…

This study tests a new drug called lunsekimig in adults aged 40-80 with COPD that is not well controlled despite standard treatments. The goal is to see if the drug can reduce the number of moderate-to-severe flare-ups over 48 weeks compared to a placebo. Participants will receiv…

This study tests a new drug called riliprubart against standard IVIg treatment in 160 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants currently on IVIg will be randomly assigned to receive either r…

This study tests a new injectable drug called lunsekimig in about 942 adults aged 40-80 with COPD that is not well controlled, especially those with a type linked to high eosinophils (a kind of white blood cell). Participants will receive either the drug or a placebo for about 48…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. Participants will receive different doses of the drug or a placebo for up to 52 weeks to see if it reduces gut inflammation and improves symptoms. The goal is to find a s…

This study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…

This study tests an investigational drug called duvakitug in people with moderate-to-severe ulcerative colitis who have already responded to treatment. The goal is to see if duvakitug can help maintain remission better than a placebo over 40 weeks, with an optional long-term exte…

This study tests whether dupilumab, an injectable drug, can reduce mucus plugs (blockages) in the lungs of people with moderate-to-severe COPD. About 218 current or former smokers aged 40-85 will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if the d…

This Phase 2 study tests brivekimig, an injected drug, in 208 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses and tunnels. Participants receive different doses of brivekimig or a placebo for up to 48 weeks. The main…

This study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …

This study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…

This study tests an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. Participants will also use standard steroid creams. The goal is to see if the drug can clear or nearly clear the skin com…

This study tests the drug belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and whose condition has not improved with at least two prior treatments. The trial has two phases: the first finds th…

This study tests an oral drug called rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. About 90 adults who have not responded well to steroids will receive either rilzabrutinib or a placebo for 24 weeks, follo…

This first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses i…

This study looks at whether it is safe for males aged 12 and older with severe hemophilia A to switch from their current medicine (emicizumab) to a new one called fitusiran. About 20 participants will be followed for up to 28 months to check for side effects and how well the new …

This study tests a gene therapy called SAR446268 for people aged 10 to 55 with myotonic dystrophy type 1. The therapy is given once through an IV and aims to reduce harmful DMPK RNA and improve muscle function. The trial has two parts: first, finding the safest dose in a small gr…

This study follows 1,000 people with Stage 2 Type 1 Diabetes who have received teplizumab in routine care. Researchers will track how long it takes for the disease to progress to Stage 3 and assess quality of life. The goal is to see if teplizumab delays the need for insulin ther…

This study is for children and teens aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a condition that causes joint swelling and fever. Researchers are testing different doses of the drug sarilumab to find the best amount that works and is safe. The study involves…

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This phase 2 trial tests two doses of rilzabrutinib, an oral drug, in 30 adults with Graves' disease (with or without eye problems). The main goal is to see if the drug lowers high thyroid hormone levels over 16 weeks. Researchers will also monitor safety and side effects.

This study tests a new drug called duvakitug in about 980 people with moderate-to-severe ulcerative colitis. Participants receive either duvakitug or a placebo as an injection under the skin for up to 12 weeks. The goal is to see if the drug can help achieve remission, meaning le…

This study tests a new drug called SAR442970 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 99 adults will receive either the drug or a placebo to see if it can help control the disease and reduce symptoms…

This study follows 200 people with stage 2 type 1 diabetes (early, no symptoms yet) who are taking TZIELD to delay the disease from getting worse. Researchers will watch for side effects over time, including serious infections and allergic reactions. The goal is to make sure the …

This phase 2 trial is testing an experimental drug called SAR442970 in about 99 adults with moderate to severe Crohn's disease. Participants will receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug can improve the appearance of the g…

This early-stage study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The study has two parts: first, finding the safest and most effective dose, the…

This study tests if dupilumab, an injected drug, can help control asthma and severe wheezing in children aged 2 to 6. About 90 kids will receive either dupilumab or a placebo for a year, with an option to continue treatment. The goal is to see if it reduces serious asthma attacks…

This study tests whether a combination insulin drug (iGlarLixi) works better than standard insulin (Gla-100) at keeping blood sugar within a healthy range throughout the day. About 678 Chinese adults with type 2 diabetes who are not well controlled on oral medications will use a …

This study tests an experimental drug called SAR444336 in 54 adults with microscopic colitis who are currently in remission using budesonide. The goal is to see if the drug can help them stay symptom-free without needing budesonide. Participants will receive either the study drug…

This study tests a new method of giving the drug isatuximab (Sarclisa) under the skin using a wearable device, combined with two other drugs (carfilzomib and dexamethasone), in 64 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is t…

This study tests the drug dupilumab (Dupixent) in 18 children aged 6 months to 18 years with prurigo nodularis, a condition causing very itchy skin bumps. The main goals are to measure how the drug moves through the body and to check for side effects. Participants receive injecti…

This study follows 350 adults with uncontrolled COPD who are starting dupilumab, a medication that reduces lung inflammation. Researchers will track changes in quality of life and breathing symptoms over two years using simple questionnaires. The goal is to see how well the drug …

This early-stage study tests an experimental drug called SAR448501 in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goal is to find the safest and most effective dose by monitoring side effects …

This study tests a new drug called SAR402663, given as a single injection into the eye, for people with wet age-related macular degeneration (AMD). The goal is to see if one dose can safely control the disease and reduce the need for frequent anti-VEGF injections. About 66 partic…

This study tests whether a once-weekly infusion of efanesoctocog alfa can improve joint swelling (synovial hypertrophy) in people with moderate to severe hemophilia A. Researchers will use ultrasound to measure changes in joint health over 12 months. The trial enrolls 35 particip…

This study in Taiwan will follow about 100 people with moderate to severe hemophilia A who are already taking efanesoctocog alfa (a clotting factor) as part of their routine care. Researchers will track joint health, bleeding rates, and safety over up to 5 years using medical rec…

This study tests a new vaccine (PCV21) designed to protect babies against 21 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 2,200 healthy infants will receive four doses of either the new vaccine or an existing one starting at 2 mont…

This study tracks the safety of Beyfortus (Nirsevimab) in up to 3,000 Korean children under 24 months who receive the shot to prevent RSV. Researchers will monitor for side effects and serious events over 180 days. It is a real-world safety check, not a test of how well it works.

This study tests if dupilumab can reduce severe itching in adults with chronic pruritus of unknown origin (CPUO) — a condition where people itch for months without a clear cause. About 284 adults aged 18 to 90 will receive either dupilumab or a placebo for 24 weeks, alongside sta…

This study tracks 184 people with moderate-to-severe atopic dermatitis (eczema) who are already starting dupilumab treatment. Over six months, researchers will measure changes in anxiety, depression, and quality of life using standard questionnaires. The goal is to see if treatin…

This early-stage study is testing whether adding an enzyme called berahyaluronidase alfa changes how the body processes dupilumab (Dupixent), a drug used for conditions like eczema and asthma. Forty healthy adults will receive a single injection of dupilumab either with or withou…

This study is a registry that will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments people use, how long they take them, and why they change or stop. The goal is to better unde…

This study observes how many eligible infants in Queensland receive the RSV immunisation (nirsevimab) during their first RSV season. Researchers will survey 1,200 parents to understand why they chose for or against the shot, and look at factors like location and health risks. No …

This study observes 60 people with stage 2 type 1 diabetes who received teplizumab as part of managed access programs. Researchers will review medical records to describe patient characteristics, monitoring practices, and how long it takes for diabetes to progress. The goal is to…

This study will follow 600 adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already taking systemic medications. Researchers will track which treatments are used, how long patients stay on them, and how well they follow their regimen. The goal is …

This study is observing 2,500 people with asthma to learn more about their symptoms, treatments, and quality of life in everyday settings. Participants will fill out surveys and may provide blood samples or lung function tests. The goal is to better understand how asthma affects …

This study watches 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers collect information from medical records and patient surveys to see how the drug works in real life, its safety, and how it affects qual…

This study follows about 500 adults with COPD who are already taking dupilumab as part of their regular care. Researchers will collect health information over 3 years to see how patients are doing and check for any side effects. The goal is to learn more about the real-world effe…

This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal care. Researchers will collect information on medical history, symptoms, and quality of life over two years to see how well the treatment works in real-world setti…

This study is screening children and adolescents aged 1.5 to 18 years who have a parent or sibling with type 1 diabetes. Researchers will collect blood samples to look for early signs of the disease, such as specific autoantibodies, before symptoms appear. The goal is to identify…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their normal care. Researchers will track symptoms, quality of life, and disease control over two years using questionnaires and checkups. The goal is to see how wel…

This study looks at over 500,000 patient records to see if diagnostic codes in electronic health records accurately identify chlamydia infections. Researchers will compare these codes with lab test results. The goal is to improve how real-world data is used for chlamydia research…

This study gathers safety information from about 100 women with Pompe disease who received Nexviazyme while pregnant or breastfeeding, and from their babies. Researchers will track pregnancy complications, birth outcomes, and infant growth and development through the first year o…

This study follows 550 people with stage 2 type 1 diabetes in the U.S. to see how teplizumab affects their quality of life, anxiety, and diabetes management. Some participants received teplizumab, others did not, and researchers compare their experiences over time. The goal is to…

This study follows up to 10 children under 2 years old with acid sphingomyelinase deficiency (ASMD) who are already receiving olipudase alfa (Xenpozyme®) as part of their routine care. Researchers will monitor side effects and immune responses over 1 to 3 years. No new treatment …